1 citations
,
January 2024 in “Journal of molecular structure” The new finasteride delivery system using chitosan-based nanoniosomes shows promise for prostate cancer prevention.
September 2004 in “Inpharma Weekly” April 2026 in “ACS Applied Materials & Interfaces” Sper-12 nanoparticles may help treat hair loss by delivering siRNA to target androgen receptors.
January 2015 in “Current Opinion in Endocrinology, Diabetes and Obesity” March 2005 in “Current Prostate Reports”
225 citations
,
July 2007 in “The Journal of Sexual Medicine” Knowing about finasteride's sexual side effects increases reported dysfunction.
December 2022 in “Acta Ophthalmologica” Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.
34 citations
,
July 2011 in “International journal of pharmaceutics” Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.
August 2012 in “Reactions Weekly” Finasteride users with sexual issues often experience depression.
2 citations
,
March 2018 in “Current Opinion in Urology” 5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
16 citations
,
October 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
35 citations
,
April 2013 in “Sexual medicine reviews” 5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.
7 citations
,
October 2009 in “Journal of the American Geriatrics Society” Finasteride may help reduce inappropriate sexual behaviors in dementia patients with prostate issues.
5 citations
,
August 2018 in “Sexual Medicine Reviews” 5α-Reductase inhibitors do not consistently increase testosterone levels in the blood.
81 citations
,
July 2012 in “Translational Psychiatry” Memantine may slightly improve memory in people with Down syndrome, but more research is needed.
January 2017 in “프로그램북(구 초록집)”
October 2008 in “The Journal of Urology” Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.
7 citations
,
April 2021 in “Journal of Clinical Psychopharmacology” Finasteride may increase the risk of depression, anxiety, and suicidal thoughts.
January 2025 in “Drug repurposing” New drug uses show promise but need more research.
December 2023 in “Alzheimer's & Dementia” Long-term use of a drug for hair loss and prostate issues can cause metabolic problems and depression-like behavior in young male rats.
2 citations
,
February 2023 in “BJUI” Urologists should monitor mental health in patients taking finasteride due to potential links to suicidal thoughts, adjusting dosage or stopping use if necessary. More research is needed to confirm if finasteride causes these thoughts.
July 2025 in “Saudi Journal of Medicine and Public Health” 5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
37 citations
,
April 2008 in “The Cochrane library” 5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
5 citations
,
August 2023 in “The World Journal of Men s Health” Red ginseng oil improves urinary symptoms and some sexual functions in men safely.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
56 citations
,
July 2014 in “PLoS ONE” Midazolam reduces PTSD-like behavior in rats by acting on specific brain receptors.
19 citations
,
September 2013 in “Psychoneuroendocrinology” Blocking CYP17A1 enzyme may help improve certain brain function issues related to dopamine.